Compare Cincinnati Financial Corporation (CINF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Sanofi SA — how do they compare? Cincinnati Financial Corporation trades at $172.82 (market cap $26.58B), while Sanofi SA trades at $43.58 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3.9× Cincinnati Financial Corporation's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| CINF | SNY | |
|---|---|---|
Market Cap | $26.58B | $104.30B |
Sector | Financials | Health |
52-Week High | $192.03 | $52.34 |
52-Week Low | $149.79 | $41.33 |
Enterprise Value | $25.71B | $124.19B |
Dividend Yield | 2.17% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $172.87, down 0.57% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 earnings miss ($1.43 vs. $1.84 expected) but maintains robust revenue growth and profitability with a 23.84% net income margin. Cash flow trends show improvement, with 2025 net cash flow reaching $448 million. Analyst consensus remains positive with a $195 price target, though technical indicators suggest near-term pressure.
CINF presents a value opportunity with attractive valuation metrics (P/E 8.18, P/B 1.59) and consistent dividend growth. Key risks include catastrophe losses impacting underwriting results and commercial lines performance. The stock's current technical weakness may offer entry points for long-term investors seeking quality insurance exposure with strong ROE of 21.48%.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
